Drug Approval | March 10, 2026
FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Subscribe To Our Newsletter & Stay Updated
